Eric J. Duncavage, MD

Professor, Pathology & Immunology

Divisions

Genomic and Molecular Pathology

Division: Genomic & Molecular Pathology

Titles

Division Chief, Genomic and Molecular Pathology

Education

Hematopathology Fellow: University of Utah/ARUP lab, Salt Lake City, UT (2009-2010)

Molecular Genetic Pathology Fellow: Washington University, St. Louis, MO (2008-2009)

Resident Physician, Anatomic and Clinical Pathology: Washington University/Barnes-Jewish Hospital, St. Louis, MO (2004-2008)

Medical Degree: University of Tennessee College of Medicine, Memphis, TN (1999-2004)

Cum Laude, Majors in Physics and Chemistry: Vanderbilt University, Nashville, TN (1994-1998)

Tennessee Honors Diploma: Brentwood High School, Brentwood, TN (1990-1994)

Boards

Board Certified in Anatomic and Clinical Pathology

Board Certified in Molecular Pathology

Board Certified in Hematopathology

Board Certified in Clinical Informatics

NY State Certificate of Qualification (Histology and Molecular)

Recognition

Harry Hill Departmental Research Grant, University of Utah, 2009

College of American Pathologists (CAP) Research Training Grant, 2009

Pulmonary Pathology Society Trainee Research Award, USCAP 2009

American Medical Association Resident Research Grant, 2008

CAP Fall Informatics Meeting (APIII) Travel Grant, 2007

CAP Spring Informatics Meeting Travel Grant, 2007

University of Tennessee Alumni Achievement Research Award, 2004

Howard Hughes Medical Institute Predoctoral Fellowship, 2001

NIH Summer Medical Student Research, Fellowship Recipient, 2000

Honorable Mention–Tennessee Biomedical Research Fair, 1998

Research Interests

Dr. Duncavage is a professor in the Department of Pathology and Immunology at WashU Medicine in St. Louis, MO and is a member of the Siteman Cancer Center. He currently serves as the director of Genomic and  Molecular Pathology Division and is the former director of the hematopathology section.  Dr. Duncavage is board certified in anatomic pathology, clinical pathology, molecular pathology, hematopathology, and clinical informatics.  His clinical practice includes sign out of blood, bone marrow, lymph nodes, and molecular diagnostics cases. As the director of molecular oncology, Dr. Duncavage oversees molecular testing in the regulated CAP/CLIA environment including the design and implementation of cutting-edge assays such as MyeloSeq®-HD, a first to market UMI-based NGS assay for the detection of measurable residual disease in myeloid neoplasms, and ChromoSeq®, a first to market comprehensive WGS-based assay for myeloid neoplasms. Dr. Duncavage’s research is focused on understanding the biology of myeloid neoplasms such as MDS and AML and developing better clinical diagnostics using sequencing-based approaches. This work is funded through several NIH and foundation awards and has resulted in multiple high-profile publications.

Selected Publications

WashU Medicine Profile

Assistant

Daniela Salazar

Administrative Professional